These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 9201802)
41. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214 [TBL] [Abstract][Full Text] [Related]
42. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia. Paquet F; Soucy JP; Stip E; Lévesque M; Elie A; Bédard MA J Neuropsychiatry Clin Neurosci; 2004; 16(1):47-56. PubMed ID: 14990759 [TBL] [Abstract][Full Text] [Related]
43. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Farde L; Suhara T; Nyberg S; Karlsson P; Nakashima Y; Hietala J; Halldin C Psychopharmacology (Berl); 1997 Oct; 133(4):396-404. PubMed ID: 9372541 [TBL] [Abstract][Full Text] [Related]
44. Relation between cortical dopamine D(2) receptor occupancy and suppression of conditioned avoidance response in non-human primate. Takano A; Suhara T; Maeda J; Ando K; Okauchi T; Obayashi S; Nakayama T; Kapur S Psychiatry Clin Neurosci; 2004 Jun; 58(3):330-2. PubMed ID: 15149302 [TBL] [Abstract][Full Text] [Related]
45. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Kapur S; Zipursky RB; Remington G Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565 [TBL] [Abstract][Full Text] [Related]
46. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia. Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809 [TBL] [Abstract][Full Text] [Related]
47. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Chernet E; Martin LJ; Li D; Need AB; Barth VN; Rash KS; Phebus LA Life Sci; 2005 Dec; 78(4):340-6. PubMed ID: 16139310 [TBL] [Abstract][Full Text] [Related]
48. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine. Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T Int J Neuropsychopharmacol; 2011 Feb; 14(1):83-9. PubMed ID: 20860881 [TBL] [Abstract][Full Text] [Related]
49. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian). Hodé Y; Reimold M; Demazières A; Reischl G; Bayle F; Nuss P; Hameg A; Dib M; Macher JP Psychopharmacology (Berl); 2005 Jul; 180(2):377-84. PubMed ID: 15948013 [TBL] [Abstract][Full Text] [Related]
50. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Kapur S; Remington G; Zipursky RB; Wilson AA; Houle S Life Sci; 1995; 57(10):PL103-7. PubMed ID: 7543969 [TBL] [Abstract][Full Text] [Related]
51. [Receptor occupancy and antipsychotic drug action measured by PET and SPECT]. Okubo Y; Suhara T Seishin Shinkeigaku Zasshi; 2001; 103(4):329-40. PubMed ID: 11392846 [TBL] [Abstract][Full Text] [Related]
52. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Nordström AL; Farde L; Nyberg S; Karlsson P; Halldin C; Sedvall G Am J Psychiatry; 1995 Oct; 152(10):1444-9. PubMed ID: 7573582 [TBL] [Abstract][Full Text] [Related]
53. Atypical antipsychotics: mechanism of action. Seeman P Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706 [TBL] [Abstract][Full Text] [Related]
54. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042 [TBL] [Abstract][Full Text] [Related]
55. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049 [TBL] [Abstract][Full Text] [Related]
56. Dopamine D(2) receptor blockade by haloperidol. (3)H-raclopride reveals much higher occupancy than EEDQ. Kapur S; Barsoum SC; Seeman P Neuropsychopharmacology; 2000 Nov; 23(5):595-8. PubMed ID: 11027926 [TBL] [Abstract][Full Text] [Related]
57. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Gründer G; Landvogt C; Vernaleken I; Buchholz HG; Ondracek J; Siessmeier T; Härtter S; Schreckenberger M; Stoeter P; Hiemke C; Rösch F; Wong DF; Bartenstein P Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387 [TBL] [Abstract][Full Text] [Related]
58. In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Sumiyoshi T; Kido H; Sakamoto H; Urasaki K; Suzuki K; Yamaguchi N; Mori H; Shiba K; Yokogawa K Pharmacol Biochem Behav; 1994 Mar; 47(3):553-7. PubMed ID: 7516078 [TBL] [Abstract][Full Text] [Related]
59. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Nyberg S; Farde L; Halldin C Neuropsychopharmacology; 1997 Jan; 16(1):1-7. PubMed ID: 8981383 [TBL] [Abstract][Full Text] [Related]
60. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Wadenberg ML; Kapur S; Soliman A; Jones C; Vaccarino F Psychopharmacology (Berl); 2000 Jul; 150(4):422-9. PubMed ID: 10958084 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]